Efficacy News and Research

RSS
What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

Microgel-coated mesenchymal stromal cells can reverse pulmonary fibrosis

Microgel-coated mesenchymal stromal cells can reverse pulmonary fibrosis

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

ONK Therapeutics and Trinity researchers seek to improve cellular therapies for treating cancer

ONK Therapeutics and Trinity researchers seek to improve cellular therapies for treating cancer

SARS-CoV-2 immunity persists for up to 11 months after natural infection

SARS-CoV-2 immunity persists for up to 11 months after natural infection

The potential of mRNA vaccines for a wide range of diseases

The potential of mRNA vaccines for a wide range of diseases

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

What lessons have we learned over a year into the COVID-19 pandemic?

What lessons have we learned over a year into the COVID-19 pandemic?

What is the role of monoclonal antibody therapy in treating COVID-19?

What is the role of monoclonal antibody therapy in treating COVID-19?

Boeing tested air purifiers like those widely used in schools. It decided not to use them in planes.

Boeing tested air purifiers like those widely used in schools. It decided not to use them in planes.

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines

Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines

Iksuda Therapeutics closes $47 million financing round

Iksuda Therapeutics closes $47 million financing round

Mass vaccination the only way to tackle emerging SARS-CoV-2 variants

Mass vaccination the only way to tackle emerging SARS-CoV-2 variants

Nanozymes to the rescue - potential role in fighting COVID-19

Nanozymes to the rescue - potential role in fighting COVID-19

No point vaccinating those who’ve had COVID-19: Cleveland Clinic study suggests

No point vaccinating those who’ve had COVID-19: Cleveland Clinic study suggests

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

Novel COVID-19 vaccine is safe, generates immune response in healthy adults

Novel COVID-19 vaccine is safe, generates immune response in healthy adults

New blood test helps monitor patient’s response to cancer treatment

New blood test helps monitor patient’s response to cancer treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.